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Mini Abstract 
Patients undergoing major surgery are at risk of life-threatening complications including 
systemic inflammatory response syndrome (SIRS) and sepsis. Early post-operative 
expression of TLR4 and TLR5 and their downstream signalling pathways in monocytes leads 
to over-expression of IL-6 and can predict SIRS in patients undergoing 
hepatopancreaticobiliary surgery. 
 
Running Title – Monocyte dysfunction in post-operative SIRS  
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Objective 
To study innate immune pathways in hepatopancreaticobiliary (HPB) surgical patients to 
understand mechanisms leading to enhanced inflammatory responses and identifying 
biomarkers of adverse clinical consequences. 
Summary Background Data 
Patients undergoing major abdominal surgery are at risk of life-threatening systemic 
inflammatory response syndrome (SIRS) and sepsis. Early identification of at-risk patients 
would allow tailored post-operative care and improve survival. 
Methods 
Two separate cohorts of patients undergoing major HPB surgery were studied (combined 
n=69). Bloods were taken pre-operatively, on day 1 and day 2 post-operatively. Peripheral 
blood mononuclear cells and serum were separated and immune phenotype and function 
assessed ex vivo. 
Results 
Early innate immune dysfunction was evident in 12 patients who subsequently developed 
SIRS (post-operative day 6) compared to 27 who did not, when no clinical evidence of SIRS 
was apparent (pre-operatively or days 1 and 2). Serum interleukin (IL)-6 concentration and 
monocyte TLR/NF-DB/IL-6 functional pathways were significantly upregulated and 
overactive in patients who developed SIRS (p<0.0001). Interferon alpha-mediated STAT1 
phosphorylation was higher pre-operatively in patients who developed SIRS. Increased TLR4 
and TLR5 gene expression in whole blood was demonstrated in a separate validation cohort 
of 30 patients undergoing similar surgery. Expression of TLR4/5 on monocytes, particularly 
intermediate CD14++CD16+ monocytes, on day 1 or 2 predicted SIRS with accuracy 0.89-1.0 
(areas under receiver operator curves). 
Conclusions 
These data demonstrate the mechanism for IL-6 overproduction in patients who develop 
post- operative SIRS and identify markers that predict patients at risk of SIRS 5 days before 
onset of 30 patients undergoing similar surgery. Expression of TLR4/5 on monocytes, 
particularly intermediate CD14++CD16+ monocytes, on day 1 or 2 predicted SIRS with 
accuracy 0.89-1.0 (areas under receiver operator curves). 
Introduction 
 
The systemic inflammatory response syndrome (SIRS) is associated with significant patient 
morbidity and mortality.1 SIRS is a clinically-defined state that represents activation of 
inflammatory, innate immune, coagulation and repair pathways and is frequently observed in 
hospitalised patients. Overall, there is a 7-fold increase in 28 day mortality in hospitalised 
patients with SIRS compared to those without.2 The incidence of post-operative sepsis (SIRS 
plus presumed or confirmed infection) is high in major operations; 16.7% following distal 
pancreatic resections,3 or 32-46% in digestive and gynaecological tumour resections.4 
Identification of patients at risk of SIRS would allow pre-emptive therapy that may improve 
outcomes. 
 
A key step in the initiation of SIRS is activation of pattern recognition receptors (PRRs) by 
pathogen associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs).5 A wide range of PRRs have been described including membrane bound Toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs), or cytoplasmic receptors such as NOD- 
like receptors (NLRs) and RIG-I-like receptors (RLRs). The paradigm for PRR activation is 
TLR4 interacting with lipopolysaccharide (LPS), a component of Gram-negative bacteria. 
There are at least 11 other members of the TLR family in humans and each is associated with 
activation by particular PAMPs.6 TLR5 is activated by flagellin, which is a component of 
motile bacteria.7 Following receptor ligation, adapter proteins are recruited and intracellular 
signalling pathways eventually lead to the activation (phosphorylation) of key transcription 
factors such as NF-DB and ERK1/2 amongst others.8, 9  These in turn drive the production of 
important pro- and anti-inflammatory cytokines such as IL-6, TNF-D and IL-10.10 
 
Following surgery, dysregulated release of pro-inflammatory cytokines has been associated 
with post-operative complications. Many groups have attempted to identify biomarkers that 
predict poor outcomes following surgery, but the majority of these tests are inconvenient to 
run in a clinical setting or involve unwieldy or expensive techniques.11, 12 Despite this 
complexity, several reports have suggested that an elevated IL-6 concentration in the early 
post-operative period is a good predictor of post-operative SIRS.4, 13 
 
Complex abdominal surgery can lead  to  the  release of  a  broad  array of  PRR  agonists 
including DAMPs released from the trauma itself, PAMPs released from commensal (e.g. due 
to gut translocation) or environmental contamination. In specialist surgical centres with 
technical expertise and dedicated peri-operative care, it is likely that the release of DAMPs 
and PAMPs related to the surgical procedure is relatively constant across patients, suggesting 
that this is not the only determinant that distinguishes patients who develop SIRS from those 
who do not. We hypothesise that the development of SIRS is a function of the responsiveness 
of host innate immune systems – principally circulating monocytes – to a given DAMP or 
PAMP load. In this study, we have focused on TLR4 and TLR5 and their bacterial ligands as 
examples of PRR sensing systems and also because Gram negative (LPS) and motile 
(flagellin) bacteria are representative of the majority of commensal bacteria likely to be 
liberated during surgery, for example Escherichia coli. Our aim was to study the TLR 
pathways involved in IL-6 production in patients at high risk of SIRS with the goal of 
identifying early biomarkers of an enhanced inflammatory response with adverse clinical 
consequences. 
 
 
 
 
 
Materials and Methods 
 
Patient selection 
We included adult patients who were undergoing major liver or pancreatic 
(non-emergency) resection at Barts Health HPB Centre between August 2011 and November 
2013 and who gave written informed consent. Exclusion criteria were active concurrent 
inflammatory disease (e.g. inflammatory bowel disease, rheumatoid arthritis), pre-operative 
sepsis and treatment with chemotherapeutic or regular anti-inflammatory medications. 
 
Data collection 
Demographic, clinical, haematological and histological data were collected prospectively 
from patient notes and the Electronic Patient Record system and included information on co- 
morbidities, indication for surgery, cancer diagnosis, duration of the procedure, length of 
hospital stay and in-hospital mortality. Patients were examined and observations charts 
reviewed daily by the clinical team for the presence of SIRS or infection, starting on the 
morning after surgery (Day 1). SIRS was defined according to international convention when 
two or more of the following criteria were present: 1. body temperature <36°C or >38°C; 2. 
heart rate >90 beats per minute; 3. tachypnoea with breathing rate >20 breaths per minute and 
4. peripheral white cell count <4000 cells/mm3 or >12,000 cells/mm.3,14  Definitions of 
infection were agreed a priori by the investigators and were based on the Center for Disease 
Control and Prevention definitions.15 
 
Venous blood sampling and separation 
Bloods were taken at clinically indicated times pre-operatively, and on day 1 and day 2 post- 
operatively. Serum was collected and stored at -80°C. Peripheral blood mononuclear cells 
(PBMC) were separated by centrifugation over Ficoll Paque (GE Healthcare, Little Chalfont, 
UK) to provide a source of monocytes. The resulting interface was aspirated, washed in PBS 
and stored in 10% dimethyl sulfoxide (DMSO) freezing solution at -80°C. 
 
TLR stimulation and cytokine production 
A total of 2 x 106 PBMCs were re-suspended in 1ml complete medium (RPMI 1640 
containing 10% fetal calf serum (FCS) 10U/ml penicillin G sodium, 10μg/ml streptomycin 
sulfate), then rested for two hours and equally divided into a 12 well plate. Each well 
contained 1ml complete medium per well. The cells were stimulated with 2ng/ml S. typhi 
lipopolysaccharide (LPS, Sigma, Gillingham, UK) and 10μg/ml S. typhi flagellin (Invivogen, 
Toulouse, France) for 24h. Supernatants were stored at -80°C. IL-6, TNF-α and IL-10 
concentrations were measured in thawed supernatants and patient serum samples using 
commercially available enzyme linked immunosorbent assay (ELISA) kits (R&D Systems, 
Minneapolis, USA). 
 
Measurement of TLR4 and TLR5 cell surface expression on monocytes 
Thawed PBMCs were incubated at room temperature in the dark for 45min with a 
combination of antibodies specific for the following: CD14 (Pacific Blue, clone M5E2), 
CD16 (AlexaFluor 647®, clone 3G8), TLR4 (Phycoerythrin (PE), clone HTA125) 
(Biolegend, Cambridge, UK) and TLR5 (Fluorscein isothiocyanate (FITC), clone 85B152.5) 
(Abcam, Cambridge, UK). Specific antibody staining was determined with reference to an 
isotype-matched control obtained from the same manufacturers. Cells were fixed in 1% 
paraformaldehyde (PFA) and analysed immediately using a Beckton Dickinson Canto II flow 
cytometer. TLR4 and TLR5 expression was determined and expressed as median 
fluorescence intensity (MFI) of each marker on CD14+, using Beckton Dickinson FACS Diva 
software. 
 
Quantification of NF-DB, ERK1/2 and STAT1 phosphorylation in CD14+ cells (Multiplex 
PhosFlow) 
PBMCs were prepared as for TLR stimulation above and the contents of each well of a 6 well 
plate were re-suspended in 200µl of complete medium. Following incubation, the cells were 
aspirated from each well and transferred into FACS tubes. Each well was washed with 1ml 
complete medium to ensure complete removal of any cells that had adhered to the base of the 
well. The samples were then centrifuged at 300g for 5min and the cells re-suspended in 
complete medium complete medium to ensure complete removal of any cells that had 
adhered to the base of the well. The samples were then centrifuged at 300g for 5min and 
the cells re-suspended in complete medium. 
 
The following were added to the PBMCs in FACS tubes and incubated for 15min in a water 
bath at 37°C; 10μg/ml flagellin, 2ng/ml LPS, 10,000u/ml IFN2α, or no agonist. Cells were 
fixed in 1% PFA, permeabilized with Perm buffer III (BD Biosciences, San Jose, USA) on ice 
in the dark for 30min. PBMCs were then washed in FACS buffer (500ml PBS, 10ml FCS, 
0.1g sodium azide, 0.18g ethylenediaminetetraacetic acid (EDTA)) and the antibody cocktail 
added: anti-phosphorylated STAT1 (Fluorscein isothiocyanate (FITC)), anti-phosphorylated 
NF-kB (Phycoerythrin (PE)), anti-phosphorylated ERK1/2 (Alexa Fluor 647 (AF647)) (BD 
Biosciences, Oxford, UK) and anti-CD14 (Pacific Blue) (Biolegend, Cambridge, UK). The 
PBMCs were incubated at room temperature for 45min in the dark, washed with FACS buffer 
and re-suspended in 300µl FACS buffer and immediately analysed on a Canto II flow 
cytometer. Colour compensation and gating were performed to select CD14+ cells for analysis 
of NF-DB, STAT1 and ERK1/2 phosphorylation.   In each experiment specific antibody 
staining was determined with reference to an isotype-matched control. The data were 
analysed using WinList™ 3D version 3.1. (Verity Software House) and expressed as the 
percentage of CD14+ cells that were positive for each phospho-antigen above isotype control. 
 
Serum conditioning of healthy control PBMCs 
PBMCs from healthy controls were prepared in the same way as patient samples. In serum 
conditioning experiments, 500µl patient serum was added to each well of a 12-well plate 
prior to stimulation with the same agonists as above. Supernatants were stored at -20°C until 
analysis by ELISA. PBMCs were then used for flow cytometry as described above. 
 
Gene Expression 
Blood was collected at each time point in a PAXGeneTM blood RNA tube (PreAnalytix, 
Hilden, Germany). Total RNA was extracted using PAXGeneTM blood RNA kits 
(PreAnalytix). Samples were analysed for RNA integrity and reverse transcribed to 
complementary DNA (cDNA). Gene expression was quantified by quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR) using TLR4 and TLR5 Taqman assays 
(Applied Biosystems, Foster City, CA), which spanned the final two exons of the most 
common isoform of each gene, and were carried out on a 7900HT apparatus, Life Tech 
(Applied Biosystems, Foster City, CA) as previously described.16 Each sample was assayed in 
triplicate. Reference genes (β2 microglobulin (B2M) and Ubiquitin C (UBC)) were selected 
empirically from a panel of six.17 Relative quantification was calculated using the standard 
delta-delta methodology. Results were expressed as a normalized ratio of candidate gene / 
reference gene. 
 
Statistical analysis 
All data presented in the results section were tested for normality using the D’Agostino 
Pearson test. Continuous data were analysed using appropriate statistical tests (unpaired t 
test, Mann Whitney test) based on normality of distribution. Differences in categorical 
variables were calculated using a chi-squared or Fisher’s exact test as appropriate. All 
statistical analysis was performed using GraphPad Prism and p<0.05 was considered 
significant. 
 
Results 
 
Serum IL-6 concentrations predict post-surgical SIRS 
We examined immune parameters associated with the development of SIRS in a cohort of 39 
patients undergoing ‘high risk’ surgical procedures (Table 1). Mean patient age was 63.2 
years (range 22-85), 52% (n=20) were male, and 95% (n=37) were Caucasian (Table 1).  
A total of 24 patients underwent pancreaticoduodenectomy, 9 major liver resection, 4 distal 
pancreatectomy, 1 palliative bypass procedure and 1 excision of choledochal cyst. Of these 
39 patients, 12 (30.7%) subsequently developed SIRS between post-operative days 2 and 12 
(median day 6). The cause of each complication and the outcome are shown in Table 2. 
There were no differences in pre-operative haematology (haemoglobin/haematocrit, white 
cell count, platelets) or biochemistry (urea, creatinine, bilirubin) between patients who 
developed SIRS and those who have an uneventful recovery. The median length of hospital 
stay for patients who developed post-operative SIRS was significantly longer than for those 
who had an uneventful recovery (22 (range 12-52) vs 12 (range 6-24) days, p<0.001). All 
patients were managed with the same anaesthetic regime, and there were no differences in 
SIRS rates among the three surgeons who performed the procedures. There were no 
significant differences in intraoperative transfusion of blood products or key clinical 
parameters (haemoglobin, white cell count, creatinine, bilirubin or C-reactive protein (CRP)) 
between patients who developed SIRS and those who did not (Table 1). There were also no 
significant differences in operative time and blood loss volume, except in 6 patients who 
underwent right hemi-hepatectomy, which is a complex procedure with longer duration 
(295min vs 198min, p<0.05) and greater blood loss (2695ml vs 1344ml, p<0.01). 
 
We examined post-operative serum concentrations of selected inflammatory cytokines (Fig. 
1). Prior to the overt development of SIRS we found that serum concentrations of IL-6 were 
higher in patients who developed SIRS after surgery compared with those who did not (Fig. 
1A, 122.4pg/ml vs 92.1pg/ml on day 2, p<0.05). Of note these changes in IL-6 cytokine 
levels pre-dated changes in any of the clinical parameters assessed. Post-operative serum 
concentrations of the anti-inflammatory cytokine IL-10 were reduced in both groups of 
patients compared to preoperative levels (Fig. 1B. 211.5 pg/ml pre-operatively vs 151.1 
pg/ml on day 2, p<0.02), but there were no significant differences between groups.  
 
Monocyte TLR expression is associated with post-operative SIRS 
Ligation of microbial products by TLRs, including TLR4 and TLR5, leads to rapid 
production of pro-inflammatory cytokines such as IL-6. We tested the hypothesis that 
monocytes (a major producer of pro-inflammatory cytokines) expressed different levels of 
TLRs in patients who went on to develop SIRS. Expression levels (median fluorescence 
intensity, MFI) of TLR4 and TLR5 on CD14+ monocytes sampled on post-operative day 1 
were 2.1-fold and 2.4-fold greater respectively in patients who developed post-operative  
SIRS than in those with an uneventful recovery (Fig. 2, p<0.0001).  Similar results were seen 
on post-operative day 2, with 2.1-fold and 2.7-fold higher TLR4 and TLR5 expression (MFI) 
in patients who developed SIRS. There were no significant pre-operative differences in TLR4 
or in TLR5 expression between the two groups of patients. This level of TLR expression in 
patients did not differ significantly from that seen in monocytes from 14 healthy control 
volunteers (7 males and 7 females, mean age 37.4 years (range 21-62)). In patients who did 
not develop post-operative SIRS, there was no significant change in monocyte TLR4 and 
TLR5 expression in the peri-operative period. However, in the SIRS group, there was a 
significant increase in expression of TLR4 (p<0.0002) and TLR5 (p<0.0001) early after 
surgery (individual patient data from post-operative days 1 and 2 are shown in Supplemental 
Digital Content 1). 
 
Consistent with these data, on post-operative day 2 (but not pre-operatively, Fig. 3A) 
monocytes from patients who developed SIRS produced significantly more IL-6 following ex 
vivo stimulation with the TLR4 agonist LPS (1.11 ng/ml vs 300 pg/ml, p<0.0001) or TLR5 
agonist flagellin (892 pg/ml vs 148 pg/ml, p<0.0001) when compared with monocytes from 
patients who did not develop SIRS (Fig. 3C). Stimulation with flagellin on post-operative 
day 1 also induced more IL-6 in patients who went on to develop SIRS compared to those 
who did not (Fig. 3B, 252 pg/ml vs 132 pg/ml, p=0.02), as was the case with LPS-induced 
IL-10 production on day 1 (Fig. 3E, 275pg/ml vs 182 pg/ml, p=0.03). No differences were 
seen in TLR-mediated TNF-α (Fig. 3G-H) although the tonic production of TNF-α by 
unstimulated monocytes was significantly reduced in the immediate post-operative period 
compared with pre-operatively (pre-operative mean 200pg/ml, 109pg/ml on day 1, 91pg/ml 
on day 2, p<0.0001 ANOVA). This change was noted in both patient groups. In contrast, IL- 
6 or IL-10 production by unstimulated monocytes did not differ between pre-operative and 
early post-operative samples. 
 
These findings were unlikely to be due to the effects of stable circulating soluble mediators 
(including IL-6 itself), since changes in TLR4 or TLR5 expression and ligand-stimulated 
cytokine production could not be replicated by culturing blood monocytes from healthy 
controls in patient serum, regardless of whether or not the serum was derived from a patient 
who subsequently developed SIRS (Supplemental Digital Content 2). Following LPS and 
flagellin stimulation, there was no significant difference in IL-6, TNF-α or IL-10 production 
between PBMCs treated with sera from patients who develop SIRS or patients who did not 
(Supplemental Digital Content 3). 
 
We next sought to determine whether the observed intrinsic enhancement of monocyte TLR 
activation and cytokine production was associated with activation of canonical signalling 
pathways. We developed a multiplex assay based on the BD Bioscience PhosFlow system to 
study the phosphorylation of the key intracellular signalling molecules NF-κB, ERK1/2 and 
STAT1 (Supplemental Digital Content 4 and Fig. 4). In-line with our ex vivo cytokine 
production data, monocyte stimulation with LPS or flagellin resulted in greater NF-κB 
phosphorylation in patients who developed SIRS compared with patients who did not on 
post-operative day 1 and day 2 (Fig. 4B-C). LPS stimulation resulted in a 3.7-fold increase in 
the percentage of phosphorylated NF-κB-positive CD14+ cells on day 1 compared with non- 
SIRS patients (p<0.01) and 11.2-fold increase on day 2 (p<0.005). Flagellin stimulation 
resulted in a 3.8 fold increase in NF-κB phosphorylation on day 1 compared with non-SIRS 
patients (p<0.05) and an 8.9 fold increase on day 2 (p<0.005). 
 
ERK1/2 phosphorylation in blood monocytes was consistently lower in patients who 
developed SIRS than in patients who did not when assessed in unstimulated (p<0.04), LPS- 
stimulated (p<0.03) or flagellin-stimulated cells (p<0.03) as assessed on post-operative day 2 
(Fig. 4I). A similar trend was observed in monocytes from day 1, but these comparisons did 
not reach statistical significance. There were no pre-operative differences in unstimulated, 
LPS- or flagellin-induced NF-κB or ERK 1/2 phosphorylation. However, pre-operative 
induction of STAT1 phosphorylation by IFNα cytokine (but not LPS or flagellin) was 1.9 fold 
greater in monocytes from patients who developed SIRS compared with those who did not 
(Fig. 4D, p<0.05 by univariate analysis). 
 
Taken together, these data suggest that patients who proceed to develop SIRS have increased 
TLR4 and TLR5 expression on blood monocytes in the immediate post-operative period. The 
functional consequence of this enhanced post surgical response is increased activation of the 
NF-κB-IL-6 signalling pathway. The strong positive correlations between TLR expression 
and agonist-induced IL-6 production suggest that these phenomena are linked in vivo 
(Supplemental Digital Content 5). 
 
Elevated TLR expression on intermediate monocytes from patients who develop SIRS 
To determine which monocyte subset was involved in the altered expression of TLR4 or 
TLR5 we studied CD16 expression to distinguish classical (CD14++,CD16-) intermediate 
(CD14++,CD16+) and non-classical (CD14+,CD16++) monocytes (Supplemental Digital 
Content 6).   Pre-operatively, the proportions of intermediate monocytes were higher 
(p<0.01, Fig. 5) and those of classical monocytes lower (p<0.05) in patients who developed 
SIRS compared to those who did not, but there were no significant post-operative differences 
in these proportions. In all patients analysed here, monocyte expression of TLR4 (p<0.0001) 
and TLR5 (p<0.0001) were highest in the intermediate subset, and the increases in TLR4 and 
TLR5 levels seen in patients who proceeded to develop SIRS were restricted to this subset 
(Supplemental Digital Content 7). In keeping with the data from total monocytes, there were 
no pre-operative differences in TLR4 or TLR5 expression in any subset. However, on both 
post-operative days 1 and 2, TLR4 (p<0.0004) and TLR5 (p<0.0001) expression on 
intermediate monocytes was significantly higher in patients who developed SIRS compared 
with patients who had an uneventful recovery (Fig. 5). On day 2, TLR4 and TLR5 
expression levels were 1.5-fold higher in patients who developed SIRS compared with those 
who did not. Thus, TLR4 and TLR5 expression on intermediate monocytes progressively 
increased over time in patients who subsequently developed SIRS, whereas they remained 
constant in patients who had a non-eventful recovery. 
 
TLR5 expression predicts SIRS 
The markers of immune dysfunction identified in this cohort of patients correctly identified 
all patients who subsequently developed clinical SIRS. We calculated the area under the 
receiver-operator curve (AUROC, Fig. 6) to estimate the accuracy of those tests that could be 
performed conveniently in a clinical pathology setting as predictors of SIRS.  The AUROC, 
sensitivity, and specificity for IL-6, TLR4 and TLR5 expression on day 1 and day 2 were 
substantially greater than that for WCC on day 1, indicating greater accuracy for these tests 
compared to routine clinical parameters (Table 3). To confirm that increased monocyte 
expression in the post-operative period was associated with SIRS we took advantage of the 
availability of a second, independently collected cohort of 30 different patients from the same 
hospital undergoing similar surgery in whom whole blood gene expression profiling by 
Taqman PCR had been performed along with stored serum to assess IL-6 levels. The baseline 
demographic and clinical characteristics of patients in the confirmatory cohort were similar to 
those of the index group with no significant differences in sex, age, ethnicity, intra-operative 
time, receipt of intra-operative blood products, pre-operative biochemistry and haematology 
(Table 1 and Table 4). In the confirmatory cohort, 8 patients (26.7%) developed SIRS in the 
post-operative period, all associated with subsequent development of infection. As in the 
original cohort, patients who developed SIRS had a significantly longer in-patient stay 
(median 22 vs 9 days, p<0.001). Patients in the confirmatory cohort who developed SIRS 
had significantly greater IL-6 concentration in the serum (233.9 pg/ml vs 71 pg/ml, p=0.002) 
on day 2 but this did not reach statistical significance on day 1 (Supplemental Digital Content 
8). TLR5 gene expression increased significantly post-operatively compared to pre-operative 
samples in this cohort. In keeping with the findings from our earlier protein-based studies in 
selected monocytes, the expression of TLR5 mRNA in whole blood was 35% greater in 
patients who went on to develop SIRS compared to those who did not (Fig. 7, p<0.01). 
 Discussion 
 
SIRS is a common complication of major surgery and identifying patients who will develop 
SIRS early in the post-operative period may allow changes in management that may lead to 
improved outcomes. Here we report that serum concentration of IL-6 cytokine on post- 
operative days 1 and 2 can be used to distinguish patients who will develop SIRS from those 
who will not - a median of 5 days before the onset of clinical signs in our series. We have 
studied the mechanisms that drive IL-6 production and show that in patients who develop 
post-operative SIRS, both LPS and flagellin can drive monocyte IL-6 production to a greater 
extent than in patients who do not, and this is likely to be mediated by upregulated TLR gene 
expression, as indicated both by studies of protein expression in an experimental cohort and 
confirmed by mRNA Taqman PCR in whole blood from patients in a confirmatory cohort. 
As such, we have identified TLR expression on monocytes, especially TLR5 on intermediate 
monocytes, as early and accurate biomarkers for post-operative SIRS. 
 
IL-6 is a pleotropic inflammatory cytokine that forms an important part of the early response 
to injury or infection. It activates vascular endothelial cells increasing permeability and 
vascular leakage, stimulates the hepatic production of acute phase proteins (including C- 
reactive protein), promotes bone marrow production of inflammatory and immune cells, and 
can activate B and T lymphocytes.18 We and others have observed that IL-6 is elevated in 
patients who develop SIRS, and although IL-6 concentrations were lower in our series than 
those reported by studies of similar patient groups,4 it is a consistent finding that IL-6 levels 
on day 1 can distinguish patients who will develop SIRS from those who will not.13 We 
further investigated the mechanisms underlying these data, and detected that the TLR/NF- 
κB/IL-6 axis is over-active in patients who develop SIRS. While responses to both TLR4 
and TLR5 agonists were increased, the abnormality is specific to the NF-κB but not ERK1/2 
signalling, and only IL-6 production was elevated (not TNF-D or IL-10), suggesting that 
additional intracellular factors determine selectivity of response. Activation of NF-κB in 
CD14+ monocytes has recently been shown to be associated with poor recovery following 
orthopaedic surgery (recovery from fatigue, functional impairment of the hip, and pain after 
surgery), although this study did not explore the mechanisms or pathways that result in 
transcription factor activation.19 
 
We have focussed on two key TLRs that mediate host responses to bacterial products, LPS 
and flagellin that together represent a large proportion of bacteria found in the gut and 
elsewhere, although the exact source of these products is as yet unclear. The role of 
additional DAMPs or PAMPs and any of the over 40 PRRs (e.g. lipoteichoic acid ligation of 
TLR2 or uric acid and NALP3) is currently unknown. We postulate that pro-inflammatory 
signals (PAMPs or DAMPs), perhaps from dead cells or from host commensal bacteria are 
liberated during surgery and may act as potential triggers of inflammation. 
 
TLR-mediated production of type 1 IFN (IFND/DD is a very early step in the initiation of 
inflammation. Autocrine and paracrine type 1 IFN binds to the cognate receptor and activates 
signalling mediators including STAT1 and STAT2, which in-turn drive 
IRF-mediated gene expression and amplify the response.20 It is therefore of particular interest 
to note pre-operative differences in IFNα-induced STAT1 phosphorylation between patients 
who develop SIRS and those who do not. One attractive hypothesis is that individuals who 
develop SIRS are pre-disposed to excessive inflammation with a ‘primed’ STAT1 response. 
For a given degree of tissue damage, endogenous bacterial translocation (or an alternative 
stimulus), this ‘pre-primed’ state facilitates a more robust inflammatory response, which may 
include expression of TLRs (known IFN stimulated genes).21 In keeping with this, we have 
shown an increased abundance of TLR5 mRNA in patients who develop SIRS. However our 
data do not allow us to identify the mediator of the change, although inhibitors of TLR and 
IFN signalling – such as suppressor of cytokine signalling (SOCS) and protein inhibitor of 
activate STATs (PIAS) proteins are potential candidates. 
 
Patients who develop SIRS have a greater proportion of CD14++/CD16+ (intermediate) 
monocytes pre-operatively. Intermediate monocytes are considered pro-inflammatory with 
greater production of TNF-D and IL-1D following stimulation with LPS, increased interaction 
with endothelial cells and greater chemokine production compared to other subsets.22     We 
show that intermediate monocytes express higher levels of TLR423 and TLR5 (previously not 
known) than CD14+/CD16- classical or CD14+/CD16++ non-classical monocytes at all time 
points. The increased expression of TLR4 and TLR5 detected on monocytes from patients 
who develop SIRS was restricted to the intermediate subset, and accordingly, the accuracy of 
predicting SIRS is increased by measuring TLR4 and TLR5 on intermediate monocytes only 
(compared with total monocytes). 
 
The incidence of post-operative SIRS in our main cohort was 31.7%, and SIRS was 
associated with a significantly increased length of hospital stay (22 days vs 13 days) and a 
higher mortality rate (15.3%). Despite the heterogeneity of the operations included in this 
study, these outcomes are in keeping with published data24, 25 suggesting that our conclusions 
are applicable more widely. The diagnostic accuracy of the tests proposed in this study will 
now require validation in a larger, independent cohort that includes patients undergoing a 
broader range of surgery, and it may be possible to refine our protocols yet further to enable 
these tests to be conducted in a routine clinical setting. 
 
The patients who developed SIRS in this study had worse outcomes than those who did not 
develop SIRS, in terms of length of hospital stay, use of intravenous antibiotics, return to 
HDU or further radiological or surgical procedures. Organ dysfunction was not a common 
feature and only seen in the patients who died. This highlights the potential clinical utility of 
the markers we identify as sensitive indicators of events that can be avoided or whose impact 
can be reduced (e.g. by the early introduction of antibiotics), rather than indicators of extreme 
complications that are likely to be irredeemable. 
 
Currently-used ‘early warning’ scoring systems are based on routinely collected clinical data, 
but these can be difficult to interpret in post-operative patients in whom clinical observations 
may already be deranged. These scores are therefore unable to identify patients at risk until 
SIRS is established, or nearly established. Our current experience suggests that this is too 
late to implement preventative measures such as low-dose glucocorticoids, antibiotics and/or 
prolonged stay on the high-dependency unit. In contrast, the novel approach that we propose 
may permit the use of interventions that are targeted against key inflammatory mediators of 
SIRS pathogenesis early after surgery, particularly given that none of the patients in the 
current study had met SIRS criteria at the time of blood sampling. This suggests that at this 
time, general or specific interventions can be implemented to avert SIRS. Although targeted 
therapies such as specific TLR4 inhibitors did not alter outcomes in patients with severe 
sepsis,26, 27 this may be due to the fact that patients were already critically unwell and at 
advanced stages of SIRS when given a TLR4 antagonist. We hypothesise that treating 
patients with TLR4 inhibitors or agents that impair signalling through TLR5 or NF-kB may 
provide therapeutic benefit before the clinical manifestations of SIRS or sepsis become 
apparent. 
 
In conclusion, we have identified a novel mechanism by which innate immune dysfunction 
occurs early in the post-operative period in patients who develop SIRS – long in advance of 
clinical signs. Abnormally elevated IL-6 levels in patients who will develop SIRS are related 
to upregulated TLR4 and TLR5 expression and preferential activation of NF-DB.   We 
hypothesise that prior to surgery, patients who develop SIRS exhibit an increased proportion 
of intermediate monocytes that are primed to react in this way. Clearly more work is needed 
to develop the clinical application of the markers we have identified here. However, we 
believe that the strategy we have employed here to study the mechanisms of disease have 
identified novel biomarkers as well as potential targets for therapeutic intervention. 
Figure & Table Legends: 
 
Figure 1. Serum IL-6 concentration is greater in patients who develop post-operative 
SIRS. 
Figure 2. Increased expression of TLR4 and TLR5 on CD14+ monocytes sampled in the 
early post-operative period predicts development of post-operative SIRS. 
Figure 3. Effects of TLR stimulation on peripheral blood mononuclear cell cytokine 
production following major HPB surgery. 
Figure 4. Increased TLR-mediated NF-kB phosphorylation in CD14+ monocytes 
sampled in the early post-operative period predicts development of post-operative SIRS. 
Figure 5. Expression of TLR4 and TLR5 on intermediate monocytes sampled in the 
early post-operative period predicts development of post-operative SIRS. 
Figure 6. Accuracy of markers of innate immune dysfunction in predicting SIRS.  
Figure 7. Taqman TLR gene expression in whole blood sampled in the pre-operative 
period predicts the development of SIRS in a confirmatory cohort of patients. 
 
Table 1. Demographic and clinical parameters - experimental cohort. 
Table 2. Causes of SIRS and outcome in patients who developed post-operative SIRS in 
the experimental cohort. 
Table 3. Area under the receiver-operator curve for prediction of SIRS in patients 
undergoing complex HPB surgery. 
Table 4. Demographic and clinical parameters - confirmation cohort. 
 
 
References 
1. Ferraris VA, Ballert EQ, Mahan A. The relationship between intraoperative blood 
transfusion and postoperative systemic inflammatory response syndrome. Am J Surg 2013; 
205:457-65. 
2. Comstedt P, Storgaard M, Lassen AT. The Systemic Inflammatory Response 
Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. Scand J 
Trauma Resusc Emerg Med 2009; 17:67. 
3. Kelly KJ, Greenblatt DY, Wan Y, et al. Risk stratification for distal pancreatectomy 
utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. J Gastrointest 
Surg 2011; 15:250-9, discussion 259-61. 
4. Mokart D, Merlin M, Sannini A, et al. Procalcitonin, interleukin 6 and systemic 
inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major 
surgery. Br J Anaesth 2005; 94:767-73. 
5. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511. 
6. Fallon PG, Allen RL, Rich T. Primitive Toll signalling: bugs, flies, worms and man. 
 Trends Immunol 2001; 22:63-6. 
7. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial 
flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-103. 
8. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 
 2006; 124:783-801. 
9. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and 
C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8. 
10. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 
410:37-40. 
11. Durila M, Bronsky J, Harustiak T, et al. Early diagnostic markers of sepsis after 
oesophagectomy (including thromboelastography). BMC Anesthesiol 2012; 12:12. 
12. Hinrichs C, Kotsch K, Buchwald S, et al. Perioperative gene expression analysis 
for prediction of postoperative sepsis. Clin Chem 2010; 56:613-22. 
13. Mokart D, Capo C, Blache JL, et al. Early postoperative compensatory anti- 
inflammatory response syndrome is associated with septic complications after major 
surgical trauma in patients with cancer. Br J Surg 2002; 89:1450-6. 
14. American. American College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for 
the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864- 74. 
15. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health 
care-associated infection and criteria for specific types of infections in the acute care 
setting. Am J Infect Control 2008; 36:309-32. 
16. Torrance HD, Brohi K, Pearse RM, et al. Association Between Gene Expression 
Biomarkers of Immunosuppression and Blood Transfusion in Severely Injured Polytrauma 
Patients. Ann Surg 2014. 
17. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time 
quantitative RT-PCR data by geometric averaging of multiple internal control genes. 
Genome Biol 2002; 3:RESEARCH0034. 
18. Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol 
 2009; 130:27-33. 
19. Gaudilliere B, Fragiadakis GK, Bruggner RV, et al. Clinical recovery from surgery 
correlates with single-cell immune signatures. Sci Transl Med 2014; 6:255ra131. 
20. Yarilina A, Ivashkiv LB. Type I interferon: a new player in TNF signaling. Curr 
Dir Autoimmun 2010; 11:94-104. 
21. Khoo JJ, Forster S, Mansell A. Toll-like receptors as interferon-regulated genes 
and their role in disease. J Interferon Cytokine Res 2011; 31:13-25. 
22. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection 
and inflammation. J Leukoc Biol 2007; 81:584-92. 
23. Pedraza-Sanchez S, Hise AG, Ramachandra L, et al. Reduced frequency of a 
CD14+ CD16+ monocyte subset with high Toll-like receptor 4 expression in cord blood 
compared to adult blood contributes to lipopolysaccharide hyporesponsiveness in newborns. 
Clin Vaccine Immunol 2013; 20:962-71. 
24. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive 
pancreaticoduodenectomies. Ann Surg 2006; 244:10-5. 
25. Mukherjee S, Kocher HM, Hutchins RR, et al. Impact of hospital volume on 
outcomes for pancreaticoduodenectomy: a single UK HPB centre experience. Eur J Surg 
Oncol 2009; 35:734-8. 
26. Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2- 
TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 
2013; 309:1154-62. 
27. Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice 
from lethal influenza infection. Nature 2013; 497:498-502. 
28. Mokart D, Merlin M, Sannini A, et al. Procalcitonin, interleukin 6 and systemic 
inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major 
surgery. Br J Anaesth 2005; 94:767-73. 
29. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511. 
30. Fallon PG, Allen RL, Rich T. Primitive Toll signalling: bugs, flies, worms and man. 
 Trends Immunol 2001; 22:63-6. 
31. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial 
flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-103. 
32. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 
 2006; 124:783-801. 
33. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and 
C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8. 
34. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 
410:37-40. 
35. Durila M, Bronsky J, Harustiak T, et al. Early diagnostic markers of sepsis after 
oesophagectomy (including thromboelastography). BMC Anesthesiol 2012; 12:12. 
36. Hinrichs C, Kotsch K, Buchwald S, et al. Perioperative gene expression analysis 
for prediction of postoperative sepsis. Clin Chem 2010; 56:613-22. 
37. Mokart D, Capo C, Blache JL, et al. Early postoperative compensatory anti- 
inflammatory response syndrome is associated with septic complications after major 
surgical trauma in patients with cancer. Br J Surg 2002; 89:1450-6. 
38. American. American College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for 
the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864- 74. 
39. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health 
care-associated infection and criteria for specific types of infections in the acute care setting. 
Am J Infect Control 2008; 36:309-32. 
40. Torrance HD, Brohi K, Pearse RM, et al. Association Between Gene Expression 
Biomarkers of Immunosuppression and Blood Transfusion in Severely Injured Polytrauma 
Patients. Ann Surg 2014. 
41. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time 
quantitative RT-PCR data by geometric averaging of multiple internal control genes. 
Genome Biol 2002; 3:RESEARCH0034. 
42. Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol 
 2009; 130:27-33. 
43. Gaudilliere B, Fragiadakis GK, Bruggner RV, et al. Clinical recovery from surgery 
correlates with single-cell immune signatures. Sci Transl Med 2014; 6:255ra131. 
44. Yarilina A, Ivashkiv LB. Type I interferon: a new player in TNF signaling. Curr 
Dir Autoimmun 2010; 11:94-104. 
45. Khoo JJ, Forster S, Mansell A. Toll-like receptors as interferon-regulated genes 
and their role in disease. J Interferon Cytokine Res 2011; 31:13-25. 
46. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection 
and inflammation. J Leukoc Biol 2007; 81:584-92. 
47. Pedraza-Sanchez S, Hise AG, Ramachandra L, et al. Reduced frequency of a 
CD14+ CD16+ monocyte subset with high Toll-like receptor 4 expression in cord blood 
compared to adult blood contributes to lipopolysaccharide hyporesponsiveness in newborns. 
Clin Vaccine Immunol 2013; 20:962-71. 
48. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive 
pancreaticoduodenectomies. Ann Surg 2006; 244:10-5. 
49. Mukherjee S, Kocher HM, Hutchins RR, et al. Impact of hospital volume on 
outcomes for pancreaticoduodenectomy: a single UK HPB centre experience. Eur J Surg 
Oncol 2009; 35:734-8. 
50. Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2- 
TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 
2013; 309:1154-62. 
51. Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice 
from lethal influenza infection. Nature 2013; 497:498-502. 
 Supplemental Digital Content: 
 
Supplemental Digital Content 1. Daily change in TLR4 and TLR5 expression in 
patients undergoing hepatobiliary surgery. 
 
Supplemental Digital Content 2. TLR4 and TLR5 expression on CD14+ monocytes from 
healthy volunteers with and without incubation with patient sera. 
 
Supplemental Digital Content 3. Cytokine production in supernatants from peripheral 
blood mononuclear cells from healthy volunteers with and without incubation with 
patient sera. 
 
Supplemental Digital Content 4. Representative FACS plot showing increase in 
proportion of cells with expression of phosphorylated NF-DB following stimulation with 
lipopolysaccharide (LPS) and phosphorylated STAT1 following stimulation with 
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Supplemental Digital Content 5. TLR expression and TLR-mediated cytokine 
production are correlated. 
 
Supplemental Digital Content 6. Representative FACS plot showing classical 
(CD14++CD16-), intermediate (CD14++CD16+) and non-classical (CD14+CD16++) 
monocytes. 
 
Supplemental  Digital  Content  7. Expression  of  TLR4  and  TLR5  is  higher  on 
intermediate monocytes compared to classical monocytes at all time points. Supplemental Digital 
Content 8. Serum IL-6 concentration is greater in patients who develop post-operative SIRS in 
the confirmatory cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No SIRS (n=27) SIRS (n=12) P value 
Sex Male 
14 
Ethnicity Caucasian 
26 
Female 
13 
Other 
1 
Male 
6 
Caucasian 
11 
Female 
6 
Other 
1 
p=ns 
p=ns 
Operative Factors 
Operative time (mins) 268 (135-460) 327 (170-585) p=ns 
Blood loss (mls) 773 (190-2010)   1088 (150-3200) p=ns 
Intra-operative 
transfusion (n(%)) 
7 (26) 6 (50) p=ns 
 
Pre-operative values 
Haemoglobin (g/dl) 12.8 (11-14.5) 13.1 (12-14.5) p=ns 
WCC (x103/ml) 7.9 (5.2-10) 8.1 (5.2-10.4) p=ns 
Platelets (x103/ml) 265 (129-402) 274 (138-411) p=ns 
Urea (mmol/l) 4.8 (3.8-8.6) 5.1 (3.5-8.4) p=ns 
Creatinine (Dmol/l) 81 (48-147) 79 (59-102) p=ns 
 
Post-operative day one 
Haemoglobin (g/dl) 10.2 (9.0-12.5) 10.2 (8.6-12.5) p=ns 
WCC (x103/ml) 14.1 (8.0-17.9) 13 (9.2-15.1) p=ns 
Platelets (x103/ml) 210 (98-429) 221 (104-442) p=ns 
Urea (mmol/l) 6.9 (3.9-10.5) 6.6 (4.4-10.2)  
Creatinine (Dmol/l) 81 (41-143) 75 (49-100) p=ns 
CRP (mg/l) 53 (5-108) 49 (21-76) p=ns 
Post-operative day two 
Haemoglobin (g/dl) 9.4 (7.8-12.8) 9.6 (7.9-13.0) p=ns 
WCC (x103/ml) 14.5 (7.8-24.1) 14.1 (7.5-20.3) p=ns 
Platelets (x103/ml) 198 (83-389) 202 (99-400) p=ns 
Urea (mmol/l) 6.2 (3.3-8.5) 6.3 (3.4-8.8) p=ns 
Creatinine (Dmol/l) 78 (41-150) 81 (48-167) p=ns 
CRP (mg/l) 119 (48-257) 113 (23-203) p=ns 
 
Table 1. Demographic and clinical parameters - experimental cohort. Data presented as 
mean (range) unless indicated otherwise. WCC=white cell count, CRP = C-reactive protein. 
 
 
 
 
 
Operation  Day 
SIRS/Sepsis 
criteria met 
Cause Outcome Discharge 
PPPD POD 6 Lower respiratory tract 
infection 
 
 
PPPD POD 8  Infected intra- 
abdominal collection 
IV antibiotics and transferred 
to HDU for positive pressure 
ventilation 
 
IV antibiotics. Did not require 
drainage 
POD 27 
 
 
 
POD 16 
 
PPPD POD 6 Lower respiratory tract 
infection 
 
Oral antibiotics POD 14 
 
PPPD POD 5 Infected post-operative  IV antibiotics and radiological 
 
POD 52 
collections 
 
 
DP POD 4 Lower respiratory tract 
infection 
drainage. Returned to HDU 
for supportive care 
 
IV antibiotics. Prolonged 
HDU stay 
 
 
 
POD 28 
 
Excision of 
choledochal cyst 
 
POD 2  Tachycardia and 
hypotensive with a 
raised WCC 
 
Supportive measures. No 
evidence of sepsis 
 
POD 12 
 
Right hemi- 
hepatectomy 
 
POD 6 Liver abscess IV antibiotics. Radiological 
drain inserted. 
 
POD 18 
 
DP POD 6 Lower respiratory tract 
infection 
 
IV antibiotics. POD 15 
 
PPPD POD 4 Infected post-operative 
collection 
 
IV antibiotics. Radiological 
drain inserted. 
 
POD 20 
 
PPPD POD 12  Bibasal lower 
respiratory tract 
infection 
 
IV antibiotics. POD 22 
 
Right hemi- 
hepatectomy 
 
POD 10 Lower respiratory tract 
infection 
 
Mortality 
 
IV antibiotics. POD 19 
Operation  Day 
SIRS/Sepsis 
criteria met 
Cause Outcome Death 
PPPD POD 2  Adult respiratory 
distress syndrome 
(ARDS) secondary to 
pancreatic leak 
 
PPPD POD 1  Grade 3 pancreatic 
leak. SMA thrombus 
leading to small bowel 
ischaemia 
IV antibiotics and ventilator 
and dialysis support. Re-look 
laparotomy on POD 3. 
 
 
Re-look laparotomy. Degree 
of damage to small bowel 
unsalvageable. 
POD 4 
 
 
 
 
POD 3 
 
Table 2. Causes of SIRS and outcome in patients who developed post-operative 
SIRS in the experimental cohort.   PPPD – pylorus-preserving 
pancreaticoduodenectomy, DP – distal pancreatectomy, WCC – white cell count, 
SMA – superior mesenteric artery, IV – intravenous. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter AUROC 95% CI P value Cut off* Sensitivity 
(%) 
Specificity 
(%) 
Day 1       
WCC 0.71 0.55 – 0.88 0.03 13.35x103/ ml 61.5 82.1 
IL6 0.88 0.72 – 1.03 0.006 97.7 pg/ml 75 83 
Total TLR4 0.87 0.75 – 0.99 0.0004 2000 75.0 68.2 
Intermediate TLR4 0.95 0.86 – 1.04 0.001 8793 88.9 88.9 
TLR5 0.92 0.83 – 1.00 <0.0001 2399 75.0 81.2 
Intermediate TLR5 0.89 0.74 – 1.00 0.005 5437 88.9 77.8 
Day 2       
IL-6 0.98 0.93-1.03 0.0004 97.7 pg/ml 100 83.3 
TLR4 0.93 0.83 – 1.02 <0.0001 2997 83.3 71.4 
Intermediate TLR4 0.98 0.92 – 1.04 0.0007 9515 100 88.9 
TLR5 0.97 0.92 – 1.03 <0.0001 3739 91.7 100 
Intermediate TLR5 1.00 1.00 – 1.00 0.0003 7426 100 100 
       
 
 
Table 3. Area under the receiver-operator curve for prediction of SIRS in patients undergoing complex HPB surgery. * mean 
fluorescence intensity units unless otherwise indicated.  WCC=white cell count 
 
 
 
 
 
 
 
 
No SIRS (n=22) 
 
SIRS (n=8) 
 
P value 
Sex 
(n) 
Male 
13 
Female 
9 
Male 
7 
Female 
1 
p=ns 
 
Age (years) 
 
66 (46-84) 
 
64 (47-81) 
 
p=ns 
Ethnicity 
(n) 
Caucasian 
20 
Other 
2 
Caucasian 
6 
Other 
2 
p=ns 
 
Operative Factors 
 
Operative time (mins) 
 
306 (120-620) 
 
300 (150-470) 
 
p=ns 
 
Intra-operative 
transfusion (n(%)) 
 
4 (18.2) 
 
2 (25) 
 
p=ns 
 
Pre-operative values 
 
Haemoglobin (g/dl) 
 
12.9(9.2-15.5) 
 
13.8 (7.3-15.0) 
 
p=ns 
WCC (x10
3
/ml) 
 
8.4 (4.4-13.3) 
 
9.4 (5.7-15.9) 
 
p=ns 
Platelets (x10
3
/ml) 
 
319 (180-474) 
 
254 (132-397) 
 
p=ns 
 
Urea (mmol/l) 
 
5.1 (2.8-9.2) 
 
5.9 (4.7-6.7) 
 
p=ns 
 
Creatinine (Dmol/l) 
 
75 (39-141) 
 
80 (51-101) 
 
p=ns 
 
Post-operative day one 
 
Haemoglobin (g/dl) 
 
11.3 (9.9-11.7) 
 
11.4 (9.7-12.3) 
 
p=ns 
WCC (x10
3
/ml) 
 
14.1 (8.1-23.9) 
 
16.0 (9.2-22.3) 
 
p=ns 
Platelets (x10
3
/ml) 
 
248 (141-471) 
 
240 (149-441) 
 
p=ns 
 
Urea (mmol/l) 
 
5.5 (3.3-9.4) 
 
6.7 (5.2-8.7) 
 
p=ns 
 
Creatinine (Dmol/l) 
 
70 (39-146) 
 
78 (57-101) 
 
p=ns 
 
CRP (mg/l) 
 
72 (40-95) 
 
46 (20-85) 
 
p=ns 
 
Post-operative day two 
 
Haemoglobin (g/dl) 
 
10.5 (8.9-11.1) 
 
10.5 (10.1-11.7) 
 
p=ns 
WCC (x10
3
/ml) 
 
12.8 (9.2-18.2) 
 
16.0 (10.7-22.0) 
 
p=0.02 
Platelets (x10
3
/ml) 
 
239 (149-441) 
 
210 (117-283) 
 
p=ns 
 
Urea (mmol/l) 
 
5.1 (2.3-8.7) 
 
8.2 (5.4-12.1) 
 
P<0.001 
 
Creatinine (Dmol/l) 
 
66 (35-159) 
 
80 (55-106) 
 
p=ns 
 
CRP (mg/l) 
 
146 (127-243) 
 
198 (110-244) 
 
p=ns 
Table 4. Demographic and clinical parameters - confirmation cohort. Data presented as 
mean(range) unless indicated otherwise. WCC=white cell count, CRP = C-reactive protein. 
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Supplemental Digital Content 1. Daily change in TLR4 (A, B) and TLR5 (C, D) 
expression in patients undergoing hepatobiliary surgery. Median ﬂuorescence 
intensity of TLR4 and TLR5 in patients who have an uneventful recovery (No SIRS) 
and patients who develop post-operative SIRS (SIRS). 
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Supplemental Digital Content 2. TLR4 and TLR5 expression on CD14+ monocytes from 
healthy volunteers with and without incubaDon with paDent sera. TLR4 (A) and TLR5 (B) 
expression on CD14+ monocytes from healthy volunteers with and without incubation with 
patient sera. TLR expression was evaluated on healthy PBMCs without added serum (No 
Serum), maintained in media conditioned with serum from healthy controls (HC), patients 
who had an unevenful recovery (No SIRS) or patients who developed SIRS (SIRS). 
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Supplemental Digital Content 3. Cytokine produc7on in supernatants from peripheral blood 
mononuclear cells from healthy volunteers with and without incuba7on with pa7ent sera. 
IL$6 (A, B), IL$10 (C, D) and TNF$α (E, F) produc6on expression was evaluated following 
s6mula6on with LPS (A, C, E) or ﬂagellin (B, D, F) of PBMCs without added serum (No Serum), 
maintained in media condi6oned with serum from healthy controls (HC), pa6ents who had an 
unevenful recovery (No SIRS) or pa6ents who developed SIRS (SIRS). 
  
 
 
 
 
Unstimulated 
A B 
LPS 
 
 
0.64% 21.4% 
 
pNF$κB 
 
 
 
 
 
 
 
C Uns.mulated D IFN$α 
 
1.1% 68.1% 
 
 
 
pSTAT1 
 
 
 
 
 
 
 
Supplemental Digital Content 4. Representative FACS plot showing PhosFlow. Increase in 
proportion of cells with expression of phosphorylated NFκB following stimulation with 
lipopolysaccharide (LPS, B) and phosphorylated STAT1 following stimulation with 
interferon(IFN)α (D) compared to unstimulated controls (A, C). 
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Supplemental Digital Content 5. TLR expression and TLR9mediated cytokine production are 
closely correlated.  Correlation between the pre/operative, day 1 and day 2 expression of 
TLR4 and LPS/stimulated IL/6 production (A9C) or TLR5 and ﬂagellin stimulated IL/6 
production (D9F) in patients who have an uneventful recovery (closed circles) and those who 
develop SIRS (open circles). The r2 coeﬃcient is presented with each graph. p<0.0001 for all 
correlations
  
 
 
 
 
 
 M
F
I 
M
F
I 
M
F
I 
M
F
I 
M
F
I 
M
F
I 
 
 
 
 
 
 
 
 
 
 
A  Pre-operative TLR4: monocyte subsets B 
 
Day 1 TLR4: monocyte subsets C Day 2 TLR4: monocyte subsets 
20000 
 
15000 
20000 
 
15000 
20000 
** ** 
15000 
 
10000 10000        10000 
 
5000 5000 5000 
 
0 
No SIRS SIRS No SIRS SIRS 
0 
No SIRS SIRS No SIRS SIRS 
0 
No SIRS SIRS No SIRS SIRS 
Classical Intermediate Classical Intermediate Classical Intermediate 
D E F 
Pre-operative TLR5: monocyte subsets 
12000 
 
12000 
Day 1 TLR5: monocyte subsets 
** 
 
12000 
Day 2 TLR5: monocyte subsets 
*** 
 
8000 8000 8000 
 
4000 4000 4000 
 
0 
No SIRS SIRS No SIRS SIRS 
0 
No SIRS SIRS No SIRS SIRS 
0 
No SIRS SIRS No SIRS SIRS 
Classical Intermediate Classical Intermediate Classical Intermediate 
 
 
Supplemental Digital Content 7. Expression of TLR4 and TLR5 is higher on intermediate monocytes 
compared to classical monocytes at all time points. Pre-operative (A, D), day 1 (B, F) and day 2 (C, 
F) TLR4 (AEC) and TLR5 (DEF) expression on classical and intermediate monocytes.
 
  
 
